Holen Sie sich die Stockscreener-App
14.08
0.42%
-0.06
Handel nachbörslich:
14.08
Schlusskurs vom Vortag:
$14.14
Offen:
$14.14
24-Stunden-Volumen:
428.68K
Relative Volume:
0.94
Marktkapitalisierung:
$1.06B
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-9.3245
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
-5.12%
1M Leistung:
+11.75%
6M Leistung:
+10.43%
1J Leistung:
+21.48%
1-Tages-Spanne:
$14.05
$14.47
1-Wochen-Bereich:
$13.60
$15.09
52-Wochen-Spanne:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.08 | 1.06B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
What Fibonacci levels say about Zymeworks Inc. reboundTrade Analysis Summary & Daily Profit Focused Stock Screening - Newser
Wellington Management Group LLP Lowers Position in Zymeworks Inc. $ZYME - MarketBeat
Nuveen LLC Invests $2.37 Million in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap DownWhat's Next? - MarketBeat
Zymeworks (NYSE:ZYME) Shares Gap DownWhat's Next? - MarketBeat
Detecting price anomalies in Zymeworks Inc. with AI2025 Sector Review & Fast Moving Stock Watchlists - Newser
ADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. $ZYME Stake Reduced by Redmile Group LLC - MarketBeat
Zymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LP - MarketBeat
Real time pattern detection on Zymeworks Inc. stock2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
Heatmap analysis for Zymeworks Inc. and competitorsWeekly Profit Report & Daily Stock Momentum Reports - Newser
Earnings Update: What is the earnings history of Zymeworks Inc.Product Launch & Weekly Stock Breakout Alerts - khodrobank.com
What’s the fair value of Zymeworks Inc. stockQuarterly Risk Review & Low Risk Profit Maximizing Plans - khodrobank.com
What momentum shifts mean for Zymeworks Inc.Rate Cut & AI Optimized Trading Strategy Guides - Newser
Vanguard Group Inc. Reduces Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Sentiment analysis tools applied to Zymeworks Inc.Market Risk Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Has Zymeworks Inc. found a price floorPortfolio Risk Report & Growth Focused Stock Pick Reports - Newser
Sector ETF performance correlation with Zymeworks Inc.Risk Management & Free Technical Confirmation Trade Alerts - Newser
Tema Etfs LLC Makes New $393,000 Investment in Zymeworks Inc. $ZYME - MarketBeat
How to build a custom watchlist for Zymeworks Inc.Index Update & Accurate Entry/Exit Alerts - Newser
Why Zymeworks Inc. stock attracts strong analyst attention2025 Growth vs Value & Long-Term Growth Plans - Newser
S P Trends: Is Zymeworks Inc. forming a breakout patternMarket Trend Report & Consistent Profit Alerts - khodrobank.com
Risk adjusted return profile for Zymeworks Inc. analyzedEarnings Overview Report & Accurate Technical Buy Alerts - Newser
Zymeworks Inc. $ZYME Shares Sold by Walleye Capital LLC - MarketBeat
Zymeworks Inc. $ZYME Shares Bought by AlphaQuest LLC - MarketBeat
Is Zymeworks Inc. forming a breakout patternQuarterly Risk Review & Stepwise Trade Execution Plans - khodrobank.com
Zymeworks’ Pipeline Resilience Amid ZW171 Setback: Strategic Reallocation and ADC Innovation Drive Long-Term Value - AInvest
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - AOL.com
Clinical Focus: Zymeworks Discontinues Development of ZW171 in Phase 1 Trial - Targeted Oncology
Is Zymeworks Inc. stock a good pick for beginnersJuly 2025 Pullbacks & Free Expert Approved Momentum Trade Ideas - khodrobank.com
What machine learning models say about Zymeworks Inc.2025 Fundamental Recap & Community Driven Trade Alerts - Newser
Zymeworks Inc. shares fall 3.31% intraday after discontinuing clinical development of ZW171. - AInvest
Zymeworks down after dropping anticancer agent (ZYME:NASDAQ) - Seeking Alpha
Zymeworks stock falls after discontinuing cancer drug development By Investing.com - Investing.com Australia
Zymeworks stock falls after discontinuing cancer drug development - Investing.com
Zymeworks Discontinues ZW171 Development Amidst Strategic Pipeline Focus - TipRanks
Zymeworks halts development of cancer drug after trial setback - MarketScreener
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - The Manila Times
Clinical Development Ends: Zymeworks' Cancer Drug ZW171 Shows Concerning Safety Profile in Phase 1 - Stock Titan
Aug Final Week: Can Zymeworks Inc. withstand a market correctionIPO Watch & Free High Return Stock Watch Alerts - khodrobank.com
Will Zymeworks Inc. bounce back from current supportProduct Launch & Safe Entry Trade Signal Reports - Newser
What is the Moat Score of Zymeworks Inc.July 2025 Levels & Fast Gain Swing Trade Alerts - khodrobank.com
Predicting Zymeworks Inc. trend using moving averages2025 Price Action Summary & Expert Curated Trade Ideas - Newser
Evaluating Zymeworks Inc. with trendline analysisWeekly Investment Summary & Daily Volume Surge Trade Alerts - Newser
Volume Report: Will Zymeworks Inc. be affected by tariffsJuly 2025 PreEarnings & Community Consensus Picks - khodrobank.com
What is Zymeworks Inc.’s TAM (Total Addressable Market)July 2025 Price Swings & Precise Buy Zone Identification - khodrobank.com
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):